Streetbeat News

Stock Prices

BARK

BARK shares are trading lower after the company reported worse-than-expected Q4 financial results and issued Q1 and FY25 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:06 pm

ASND

Ascendis Pharma A/S (NASDAQ:ASND) presented new data and updated results from its Phase 1/2 IL-Believe Trial at ASCO 2024. The trial showed promising clinical responses in patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ, both as monotherapy and in combination with TransCon TLR7/8 Agonist.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:05 pm

BARK

BARK has revised its FY25 revenue forecast to $490M-$500M, which is below the previous estimate of $511.338M.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:05 pm

BARK

BARK has revised its Q1 2025 revenue forecast to $113M-$116M, which is below the estimated $124.674M.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:05 pm

BARK

BARK has authorized a $15 million share buyback program, indicating confidence in its financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:03 pm

ELDN

Eledon Pharmaceuticals presented updated data on its drug Tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:03 pm

BARK

BARK (NYSE:BARK) reported Q4 sales of $121.500 million, missing the analyst consensus estimate of $122.433 million by 0.76%. This represents a 3.58% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:02 pm

HQY

HealthEquity (NASDAQ:HQY) reported strong Q1 results, with adjusted earnings per share of $0.80 beating the estimate of $0.66 and sales of $287.60 million surpassing the $278.11 million estimate. This represents significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:02 pm

SRRK

Scholar Rock (NASDAQ:SRRK) announced promising data from its Phase 1 DRAGON trial of SRK-181 in combination with pembrolizumab, showing encouraging responses in anti-PD-(L)1 resistant patients across multiple tumor types. The data were presented at the ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:01 pm

ELF

Analysts have provided 18 ratings for e.l.f. Beauty (NYSE:ELF) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $212.0, with a high of $230.00 and a low of $151.00. Recent evaluations show a slight decrease in the average price target by 0.08%.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 8:00 pm